SCHEMBL6597802

SCHEMBL6597802

CON(C)C(=O)[C@H](Cc1ccc(OCc2ccccc2)cc1)NC(=O)OC(C)(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 1/20 0.59
PTPN1 P18031 3/20 0.58
HDAC8 Q9BY41 1/20 0.55
MMP9 P14780 1/20 0.53
MMP8 P22894 1/20 0.53
REN P00797 1/20 0.53
JAK3 P52333 1/20 0.52
BTK Q06187 1/20 0.52
ITGB3 P05106 1/20 0.52
ITGA2B P08514 1/20 0.52
PSMB10 P40306 5/20 0.51
CTSS P25774 2/20 0.51
CTSL P07711 1/20 0.51
CTSB P07858 1/20 0.51
CTSK P43235 1/20 0.51
PSMB1 P20618 6/20 0.51
PSMB9 P28065 5/20 0.51
PSMB5 P28074 5/20 0.51
PSMB8 P28062 4/20 0.51
PSMB2 P49721 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5347958 1.00 BCL2 (0.59) BCL2PTPN1HDAC8MMP9MMP8
SCHEMBL5347955 1.00 BCL2 (0.59) BCL2PTPN1HDAC8MMP9MMP8
SCHEMBL1204211 0.90 JAK3 (0.61) HDAC8RENJAK3BTKCTSS
SCHEMBL6557659 0.90 JAK3 (0.61) HDAC8RENJAK3BTKCTSS
SCHEMBL9052038 0.87 ACE (0.64) PTPN1JAK3BTKITGB3ITGA2B
SCHEMBL8185213 0.87 CTSS (0.62) BCL2PTPN1HDAC8JAK3BTK
SCHEMBL9929886 0.87 CTSS (0.62) BCL2PTPN1HDAC8JAK3BTK
SCHEMBL6161729 0.86 BCL2 (0.64) BCL2PTPN1HDAC8RENITGB3
SCHEMBL3500186 0.86 BCL2 (0.64) BCL2PTPN1HDAC8RENITGB3
SCHEMBL3350988 0.86 BCL2 (0.64) BCL2PTPN1HDAC8RENITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110040087-A1 PEPTIDE TURN MIMETICS MIMETICA PTY LTD. (AU) 2011-02-17 US disclosed
EP-1081132-B1 HYDROXAMIC ACID DERIVATIVES AND MEDICINAL UTILIZATION THEREOF MITSUBISHI PHARMA CORP (JP) 2004-03-10 EP disclosed
US-6610729-B1 Inhibotors of TNF, antiinflammatory MITSUBISHI PHARMA CORPORATION (JP) 2003-08-26 US disclosed
EP-0721449-B1 INHIBITORS OF BETA-AMYLOID PROTEIN PRODUCTION MERRELL PHARMA INC (US) 2001-12-19 EP disclosed
EP-1081132-A1 HYDROXAMIC ACID DERIVATIVES AND MEDICINAL UTILIZATION THEREOF Welfide Corporation (JP) 2001-03-07 EP disclosed
EP-0742791-B1 MACROCYCLIC DIFLUOROSTATONE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS MERRELL PHARMA INC (US) 2001-01-10 EP disclosed
US-5977074-A THERAPY FOR ALZHEIMER'S DISEASE MERRELL PHARMACEUTICALS, INC. (US) 1999-11-02 US disclosed
US-5969132-A Macrocyclic difluorostatone derivatives useful as antiviral agents MERRELL PHARMACEUTICALS INC. (US) 1999-10-19 US disclosed
US-5716973-A ADMINISTERING DIFLUORO STATONE ANALOGS MERRELL PHARMACEUTICALS INC. (US) 1998-02-10 US disclosed
US-5559140-A VIRICIDES MERRELL PHARMACEUTICALS INC. (US) 1996-09-24 US disclosed
WO-1996002499-A1 DIFLUOROSTATONE ANTIVIRAL AGENTS MERRELL PHARMACEUTICALS INC. (US) 1996-02-01 WO disclosed
US-5455271-A Using aromatic amine derivitives as mosquito insecticide THE SCRIPPS RESEARCH INSTITUTE (US) 1995-10-03 US disclosed
WO-1995021186-A1 MACROCYCLIC DIFLUOROSTATONE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS MERRELL PHARMACEUTICALS INC. (US) 1995-08-10 WO disclosed
WO-1995009838-A1 INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION MERRELL PHARMACEUTICALS INC. (US) 1995-04-13 WO disclosed
WO-1994000420-A1 NOVEL TIGHT-BINDING INHIBITORS OF LEUKOTRIENE A4 HYDROLASE THE SCRIPPS RESEARCH INSTITUTE (US) 1994-01-06 WO disclosed
EP-0565631-A1 ANTI-VIRAL COMPOUNDS. MERRELL DOW PHARMA (US) 1993-10-20 EP disclosed
WO-1992012123-A1 ANTI-VIRAL COMPOUNDS MERRELL DOW PHARMACEUTICALS INC. (US) 1992-07-23 WO disclosed
EP-0434365-A2 HIV protease inhibitors useful for the treatment of aids MERCK & CO. INC. (US) 1991-06-26 EP disclosed
WO-1990000399-A1 RETROVIRAL PROTEASE BINDING PEPTIDES SMITHKLINE BECKMAN CORPORATION (US) 1990-01-25 WO disclosed
EP-0352000-A2 Retroviral protease binding peptides SMITHKLINE BEECHAM CORPORATION (US) 1990-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110040087-A1 PEPTIDE TURN MIMETICS VIP, IAPP, SCTR BCL2 4163/4885PTPN1 2173/4885HDAC8 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.